226 results on '"Aspord, Caroline"'
Search Results
2. SAT-389 HBV and HBsAg strongly reshape the phenotype, function and metabolism of DCs according to patients’ clinical stage
3. Glycans in melanoma: Drivers of tumour progression but sweet targets to exploit for immunotherapy
4. Harnessing Immune Cell Metabolism to Modulate Alloresponse in Transplantation
5. Identification of a predictive metabolic signature of response to immune checkpoint inhibitors in non-small cell lung cancer: METABO-ICI clinical study protocol
6. Melanoma tumour‐derived glycans hijack dendritic cell subsets through C‐type lectin receptor binding
7. 6. Vaccination par cellules dendritiques
8. Melanoma tumour‐derived glycans hijack dendritic cell subsets through C‐type lectin receptor binding.
9. Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation
10. Figure S3 from Impaired Antitumor Immune Response in MYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment
11. Data from Impaired Antitumor Immune Response in MYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment
12. Supplementary Figures 1 - 5, Tables 1 - 2 from Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL
13. Data from Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL
14. Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
15. The melanoma tumor glyco-code impacts human dendritic cells’ functionality and dictates clinical outcomes
16. A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients
17. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
18. Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches
19. Adenovirus-Inspired Virus-like-Particles Displaying Melanoma Tumor Antigen Specifically Target Human DC Subsets and Trigger Antigen-Specific Immune Responses
20. Unique CLR expression patterns on circulating and tumor-infiltrating DC subsets correlated with clinical outcome in melanoma patients
21. Impaired Antitumor Immune Response in MYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment
22. The avidity of tumor‐specific T cells amplified by a plasmacytoid dendritic cell‐based assay can predict the clinical evolution of melanoma patients
23. Immunotherapy Via Dendritic Cells
24. Altered Functions of Plasmacytoid Dendritic Cells and Reduced Cytolytic Activity of Natural Killer Cells in Patients With Chronic HBV Infection
25. Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80 + PDL1 − )‐pDC subset negatively correlated with clinical outcomes in melanoma patients
26. Unique CLR expression patterns on circulating and tumorinfiltrating DC subsets correlated with clinical outcome in melanoma patients.
27. Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1−)‐pDC subset negatively correlated with clinical outcomes in melanoma patients.
28. Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes
29. Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals
30. Nanoprobes to Monitor Cell Processes in the Pancreas
31. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection
32. Reply to Comment on “Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554
33. Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints
34. DNA repair-based classification of melanoma cell lines reveals an effect of mutations in BRAF and NRAS driver genes on DNA repair capacity
35. T‐cell receptor diversity as a prognostic biomarker in melanoma patients
36. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial
37. BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients
38. Hepatitis B virus exploits C‐type lectin receptors to hijack cDC1s, cDC2s and pDCs
39. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
40. Immunotherapy Via Dendritic Cells
41. Dendritic cell subsets in health and disease
42. The features of circulating and tumor-infiltrating γδ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome
43. Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection
44. BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients.
45. Abstract 2888: DNA Repair Enzyme Signature as a biomarker of MAPK pathway inhibition by targeted therapies in melanoma cell lines
46. The avidity of tumor‐specific T cells amplified by a plasmacytoid dendritic cell‐based assay can predict the clinical evolution of melanoma patients
47. Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses
48. Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model
49. Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells
50. Estrogen receptor signaling and X-chromosome complement both independently contribute to the enhanced TLR-7-mediated responses of woman plasmacytoid dendritic cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.